Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 7, 2018

Chromatography Resin Designed to Boost Process-Scale Productivity

Bio-Rad introduces CHT Ceramic Hydroxyapatite XT media and Nuvia HP-Q resin resin for process protein purification.

Bio-Rad Laboratories introduced the CHT Ceramic Hydroxyapatite XT media and Nuvia HP-Q resin for process protein purification, according to an Aug. 30, 2018 announcement.

The CHT Ceramic Hydroxyapatite XT (CHT XT) Mixed-Mode Media offers single-step clearance of aggregates and other impurities such as host-cell protein, double stranded DNA

 (dsDNA), endotoxins, and leached Protein A. It can be used in the purification of enzymes, monoclonal and polyclonal antibodies of various classes, antibody fragments, and bispecific antibodies; for isolation and purification of viruses and virus-like particles; and for separation of supercoiled DNA from linear duplexes and single-stranded from dsDNA.

The media binds by cation exchange and affinity interactions, is compatible with a range of chemicals, and its reusability improves economy of the process purification workflow, the company reports.

Nuvia HP-Q Anion Exchange Resin is compatible with high-throughput large biomolecule purification and can be used for downstream purification of large molecules such as high molecular weight plasma proteins IgA and IgM, viruses, virus-like particles, and PEGylated proteins.

The resin’s high flow rate compatibility (300 cm/hr) and fast mass transfer kinetics ensure purifications can be performed in less time. A lifetime of more than 100 cycles without loss of dynamic binding capacity (DBC) allows repeated use. The resin column holds up under the flow rates required for manufacturing-scale purification, and DBC (>50 mg/ml) with optimized pore structure, spacer length, and ligand density improves productivity, the company reports.

Source: Bio-Rad Laboratories

 


Related to this article

The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.